Progressive Multifocal Leukoencephalopathy, HIV, and Highly Active Antiretroviral Therapy
- 17 September 1998
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 339 (12) , 848-849
- https://doi.org/10.1056/nejm199809173391216
Abstract
The results of AIDS Clinical Trials Group Study 243, reported by Hall et al. (May 7 issue),1 show that neither cytarabine nor regimens of one or two reverse-transcriptase inhibitors affect the course of progressive multifocal leukoencephalopathy in patients infected with the human immunodeficiency virus (HIV). Recent case reports have indicated that neurologic conditions and survival may improve in patients with progressive multifocal leukoencephalopathy who receive highly active antiretroviral therapy, including protease inhibitors.2-4 Protease inhibitors became widely available only after the cytarabine trial.1Keywords
This publication has 5 references indexed in Scilit:
- Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Remission of progressive multifocal leucoencephalopathy after antiretroviral therapyThe Lancet, 1997
- 2·5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapyThe Lancet, 1997
- Remission of Progressive Multifocal Leukoencephalopathy Following Splenectomy and Antiretroviral Therapy in a Patient with HIV InfectionNew England Journal of Medicine, 1997
- Diagnosis of central nervous system complications in HIV-infected patientsAIDS, 1997